DRIO vs NVCR vs ABT vs NKTR

For growth investors, NovoCure Limited (NVCR) is the stronger pick with 8.

3% revenue growth year-over-year, versus -43. 9% for Nektar Therapeutics (NKTR). DarioHealth Corp. (DRIO) offers the better valuation at 6. 6x trailing P/E, making it the more compelling value choice. Analysts rate DarioHealth Corp. (DRIO) a "Buy" — based on 8 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, DarioHealth Corp.

(DRIO) is the cheapest at 6. 6x versus Abbott Laboratories at 11. 4x.

Over the past 5 years, Abbott Laboratories (ABT) delivered a total return of -17.

9%, compared to -97. 8% for DarioHealth Corp. (DRIO). Over 10 years, the gap is even starker: ABT returned +173. 7% versus DRIO's -99. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Abbott Laboratories (ABT) is the lower-risk stock at 0.

25β versus NovoCure Limited's 2. 20β — meaning NVCR is approximately 788% more volatile than ABT relative to the S&P 500. On balance sheet safety, Abbott Laboratories (ABT) carries a lower debt/equity ratio of 32% versus 166% for Nektar Therapeutics — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), NovoCure Limited (NVCR) is pulling ahead at 8.

3% versus -43. 9% for Nektar Therapeutics (NKTR). On earnings-per-share growth, the picture is similar: DarioHealth Corp. grew EPS 267. 6% year-over-year, compared to -12. 1% for Nektar Therapeutics. Over a 3-year CAGR, NVCR leads at 6. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

DarioHealth Corp.

(DRIO) is the more profitable company, earning 276. 1% net margin versus -297. 1% for Nektar Therapeutics — meaning it keeps 276. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ABT leads at 16. 3% versus -236. 8% for NKTR. At the gross margin level — before operating expenses — NKTR leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for NVCR: 99.

0% to $33. 50.

In this comparison, ABT (2.

5% yield) pays a dividend. DRIO, NVCR, NKTR do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Abbott Laboratories (ABT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

25), 2. 5% yield, +173. 7% 10Y return). NovoCure Limited (NVCR) carries a higher beta of 2. 20 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ABT: +173. 7%, NVCR: +30. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: DRIO is a small-cap deep-value stock; NVCR is a small-cap quality compounder stock; ABT is a mid-cap deep-value stock; NKTR is a small-cap quality compounder stock. ABT pays a dividend while DRIO, NVCR, NKTR do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.